The starter dose drops from $349 to $299 and the 5 mg vial from $499 to $399, with everything above 7.5 mg at $449 on a 45-day refill condition.
Eli Lilly's Self Pay Journey Program tiers, effective 23 February 2026, price Zepbound single-dose vials at $299 per month for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg and above. The higher-dose rate is conditional: you have to refill within 45 days of the previous delivery to keep it.
Miss that window and the standard self-pay price applies for that refill, reported at $599 for 7.5 and 10 mg and rising to $1,049 at 15 mg. That condition is the part most coverage omits, and it is the part that turns a predictable brand price into an unpredictable one for anyone whose delivery slips.
For anyone weighing brand against compounded, this narrows the gap at the starter dose and leaves it wide at maintenance. At 2.5 mg, $299 for an FDA-approved product is competitive with several compounded programs. At 10 mg, $449 is roughly double the cheapest verified compounded route.
We carried the older $349–$499 tiers until this was checked. That correction is logged, and it is the reason every brand figure on this site now derives from the dataset rather than from page copy.
Sources
- Eli Lilly investor press release on Zepbound single-dose vial pricing
- LillyDirect Self Pay Journey Program tiers, effective 23 February 2026
Dated 2026-02-23. If this item is out of date or wrong, tell us through contact and the change is logged in corrections.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.